Platinum-Resistant Lung Small Cell Carcinoma Recruiting Phase 2 Trials for Lurbinectedin (DB12674)

IndicationStatusPhase
DBCOND0118884 (Platinum-Resistant Lung Small Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04607954Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerTreatment